Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment
Authors:
- 1 October 2022
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 174, 1-13
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumorsNeurology, 2013
- Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancerCancer Chemotherapy and Pharmacology, 2012
- Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy eraLung Cancer, 2012
- Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain RadiotherapyJournal of Thoracic Oncology, 2012
- "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerNeuro-Oncology, 2011
- Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)Annals of Oncology, 2011
- Leptomeningeal metastasisCurrent Opinion in Oncology, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanomaJournal of Neuro-Oncology, 2009